Curcumin (CUR) is a polyphenol compound derived from the Zingiberaceae plant Curcuma longa, commonly found in spices like turmeric and curry. It has garnered significant attention for its diverse molecular interactions, impacting various pathways due to its interactions with transcription factors, receptors, enzymes, and growth factors. Known for its medicinal potential, CUR exhibits anti-inflammatory, antioxidant, antimicrobial, and anti-tumor properties by influencing vital cellular processes such as apoptosis, proliferation, and angiogenesis. Its inclusion in biodegradable polymeric nanoformulations for cancer treatment is notable for its ability to sensitize colon cancer cells and enhance the effects of anti-cancer drugs.
To address the challenges posed by conventional chemotherapy, which lacks specificity and can lead to side effects, the study focuses on developing a novel analytical approach to quantify CUR and another anti-cancer drug, capecitabine (CAP), in plasma and nanoformulations. The absence of efficient methods for simultaneous estimation of these compounds prompted the design of a reversed-phase high-performance liquid chromatography (RP-HPLC) technique. The newly developed method was meticulously validated, ensuring its accuracy, sensitivity, and robustness in determining drug concentrations crucial for therapeutic efficacy assessment.
Employing a quality by design (QbD) approach, the study optimized the analytical procedure for enhanced performance, reliability, and flexibility. By utilizing an isosbestic point in the RP-HPLC method, the researchers achieved a rapid and specific technique tailored for drug delivery applications, enabling simultaneous quantification of CAP and CUR. The validation process adhered to stringent criteria outlined in the ICH Q2 R1 guidelines, emphasizing the importance of precise analytical methods in pharmaceutical analysis.
The chromatographic separation utilized a methanol: 0.1% orthophosphoric acid mobile phase with specific conditions to ensure accurate quantification. The RP-HPLC method demonstrated linearity within a defined concentration range, with high recovery rates and precision. Notably, the approach exhibited excellent sensitivity, with low limits of detection and quantification for both CAP and CUR, enabling reliable quantification in human plasma samples. Furthermore, stress degradation studies and application to biodegradable nanoformulations confirmed the method’s robustness and applicability in complex drug delivery systems.
In conclusion, the study’s innovative RP-HPLC method, developed through a systematic QbD framework, represents a significant advancement in quantifying anti-cancer polyphenols with precision and efficiency. By combining analytical rigor with cutting-edge technology, the approach offers a reliable tool for evaluating drug compositions in therapeutic applications, paving the way for enhanced cancer treatment strategies.
Key Takeaways:
– Development of a novel RP-HPLC method enables simultaneous quantification of capecitabine and curcumin in plasma and nanoformulations.
– Quality by design (QbD) principles enhance the analytical procedure’s performance, robustness, and flexibility.
– The validated RP-HPLC approach demonstrates high sensitivity, accuracy, and precision in quantifying anti-cancer polyphenols.
– The study underscores the importance of advanced analytical techniques in optimizing drug delivery and therapeutic efficacy assessment.
Tags: chromatography, drug delivery
Read more on chromatographyonline.com